| 2.4 0.02 (0.84%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.83 | 1-year : | 4.8 |
| Resists | First : | 3.27 | Second : | 4.11 |
| Pivot price | 3.01  |
|||
| Supports | First : | 1.93 | Second : | 1.6 |
| MAs | MA(5) : | 2.37  |
MA(20) : | 3.17 |
| MA(100) : | 3.95 |
MA(250) : | 3.03 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 25.4 |
| RSI | RSI(14): 31.7 |
|||
| 52-week | High : | 5.07 | Low : | 1.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MGNX ] has closed above bottom band by 22.3%. Bollinger Bands are 169.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.44 - 2.45 | 2.45 - 2.46 |
| Low: | 2.21 - 2.22 | 2.22 - 2.23 |
| Close: | 2.38 - 2.4 | 2.4 - 2.42 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Mon, 26 Oct 2026
Four patients with clear cell gynecologic cancer responded; all four responses were ongoing at cutoff. - Stock Titan
Fri, 23 Oct 2026
MacroGenics (MGNX) Reports Promising Interim Phase 1 Data for MG - GuruFocus
Fri, 09 Oct 2026
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 07 Oct 2026
At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. - Stock Titan
Wed, 09 Sep 2026
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha
Thu, 20 Aug 2026
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 77 (%) |
| Shares Short | 7,040 (K) |
| Shares Short P.Month | 7,120 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.67 |
| Profit Margin | -8.4 % |
| Operating Margin | -42.2 % |
| Return on Assets (ttm) | -8.1 % |
| Return on Equity (ttm) | -225.9 % |
| Qtrly Rev. Growth | 378 % |
| Gross Profit (p.s.) | -0.03 |
| Sales Per Share | 2.74 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -1.42 |
| PEG Ratio | 0 |
| Price to Book value | 3.58 |
| Price to Sales | 0.87 |
| Price to Cash Flow | -2.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|